Atara Biotherapeutics (STU:AT20) EPS (Basic): €-0.65 (TTM As of Mar. 2026)


STU:AT20 Atara Biotherapeutics Inc STU:AT20
31 GF Score
Price €8.80
GF Value €1.30
! 7 Warning Signs
View Full Analysis

What is Atara Biotherapeutics EPS (Basic)?

Atara Biotherapeutics STU:AT20 31 EPS (Basic) is €-0.65 as of Mar. 2026. GuruFocus rates STU:AT20 with a GF Score™ of 31/100 and a GF Value™ of €1.30. The stock has 7 warning signs investors should review.

Atara Biotherapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €-0.25. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.65.

Atara Biotherapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.25. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.67.

Atara Biotherapeutics's EPS without NRI for the three months ended in Mar. 2026 was €-0.25. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.63.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Atara Biotherapeutics's highest 3-Year average EPS without NRI Growth Rate was 49.90% per year. The lowest was -62.50% per year. And the median was 10.70% per year.

Atara Biotherapeutics  (STU:AT20) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Atara Biotherapeutics EPS (Basic) Related Terms

Atara Biotherapeutics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Atara Biotherapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atara Biotherapeutics EPS (Basic) Chart

Atara Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -80.31 -52.86 -59.78 -10.90 2.23

Atara Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.27 0.17 -0.27 -0.30 -0.25
STU:AT20
31GF Score
Atara Biotherapeutics Inc STU:AT20
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atara Biotherapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Atara Biotherapeutics's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(27.916-0)/12.544
=2.23

Atara Biotherapeutics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-3.585-0)/14.081
=-0.25

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.65 mean?
Atara Biotherapeutics (STU:AT20) has a EPS (Basic) of €-0.65 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Atara Biotherapeutics and its competitors.
Is Atara Biotherapeutics' EPS (Basic) too high?
Atara Biotherapeutics' current EPS (Basic) is €-0.65. Overall, Atara Biotherapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Atara Biotherapeutics' EPS (Basic) compare to RNTX and IBIO?
Atara Biotherapeutics' EPS (Basic) of €-0.65 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Atara Biotherapeutics and its competitors. Atara Biotherapeutics's current EPS (Basic) is €-0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atara Biotherapeutics stock overvalued right now?
Atara Biotherapeutics (STU:AT20) has a current EPS (Basic) of €-0.65. The stock's GF Value™ is €1.30, compared to a current price of €8.80 — trading 576.7% above its estimated fair value. The current EPS (Basic) is €-0.65. Atara Biotherapeutics' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Atara Biotherapeutics (STU:AT20), the current EPS (Basic) is €-0.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atara Biotherapeutics (STU:AT20) Overvalued in 2026?

Based on GuruFocus' analysis, Atara Biotherapeutics stock appears to be overvalued. The current stock price of €8.80 is trading 576.7% above its estimated GF Value™ of €1.30.

Key valuation signals for STU:AT20:

  • EPS (Basic): €-0.65
  • GF Value™: €1.30 vs. price of €8.80 (576.7% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the STU:AT20 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atara Biotherapeutics Business Description

Other Exchanges ATRA:USA0HIY:UKAT20:Germany
Address 1280 Rancho Conejo Boulevard, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
31GF Score

Get the complete analysis for STU:AT20

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.80
Price
€1.30
GF Value